UCB SA
UCB: XBRU (BEL)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€15.00 | Nhp | Rrglnhzqk |
UCB Reports Pipeline Progress Amid Generic Competition; FVE EUR 99, Shares Undervalued
UCB reported 2022 results broadly in line with our expectations, with overall revenue of EUR 5.5 billion declining about 4% from 2021 as generic competition for Vimpat has affected sales. Vimpat is UCB’s second-largest drug (accounting for over 20% of 2022 revenue), and it reported a year-over-year decline of 27% as it lost its patent exclusivity in the U.S in early 2022.